Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151215 · ClinicalTrials.gov registry record · Phase 2
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 482
- Enrollment target
NCT01151215 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 482 participants.
The verdict
NCT01151215, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 482 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary objective is to investigate the safety and tolerability of AZD8931 given in combination with anastrozole.
Interventions
- DRUG Placebo
- DRUG anastrozole
- DRUG AZD8931
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01151215
The ClinicalTrials.gov registry entry for NCT01151215 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01151215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01151215 about?
NCT01151215 is a clinical study titled "Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer". The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary objective is to investigate the safety and tolerability of AZD8931 given in combination with anastrozole.
What is the current status of trial NCT01151215?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 482 participants. The study started on 2010-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01151215?
The interventions under investigation include: Placebo (DRUG), anastrozole (DRUG), AZD8931 (DRUG).
Who is sponsoring clinical trial NCT01151215?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.